12月15日午后，港股通创新药板块加速下跌，港股通创新药ETF（520880）一度跌至2.77%创近5个月 新低，龙头股齐挫，康方生物跌超5%，百济神州跌逾6%，中国生物制药、信达生物跌超3%。 3、风险更可控。对流动性较差的成份股强制降权，有力管控尾部风险。 | | | 港股通创新药ETF (520880) 标的指数 | | | --- | --- | --- | --- | | | | 前十成份股权重高达72.57%,龙头优势显著 | | | મદિલ્તિ | 简称 | 权重(%) | 总市值(亿港元) | | 6160.HK | 百济神州 | 11.51 | 3,070 | | 1801.HK | 信法: 参加 | 10.19 | 1,613 | | 1177.HK | 中国生物制药 | 9.47 | 1,323 | | 9926.HK | 康方生物 | 8.99 | 1,132 | | 1093.HK | 石药集团 | 8.39 | 911 | | 1530.HK | 三生制药 | 8.32 | 760 | | 3692.HK | 翰森制药 | 6.63 | 2,435 | | 6990.HK | ...

12月3日，港股创新药板块延续调整态势，龙头股集体飘绿，百济神州、信达生物、石药集团齐跌逾 1%，中国生物制药、三生制药跌超2%。 港股通创新药ETF（520880）超7成仓位押注创新药龙头股，持续水下震荡，截至发稿跌逾1%，连续第 4日下跌。不过场内延续宽幅溢价，显示买盘资金相对强势。 | | | 分时 多日 1分 5分 15分 30分 · | | | F9 發前盘后 發加 九越 画坊 丁具 @ (2) | | | 港股通创新药ETF O | | 520880 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 520880[種腔通创新药ETF] 13:19 价 0.553 涨跌 -0.007(-1.25%) 均价 0.556 成交量 | | | | | | | | | 0.570 | | | | | | | | 05 | | -0.007 -1.25% | | 0,567 | | | | | | | 1.2496 | SSE CNY 13:19:54 文明中 | | # ■ Z 版 O+1 | | | ...

Investment Rating - The industry investment rating is "Outperform the Market" and is maintained [2] Core Views - The retail pharmacy sector is expected to benefit from the recent surge in flu cases, with a significant increase in demand for antiviral medications and symptomatic treatments [5][15] - The retail pharmacy industry is anticipated to undergo accelerated consolidation, with smaller pharmacies exiting the market, leading to increased customer traffic for leading players [6][34] - The implementation of drug traceability codes is expected to enhance industry compliance and further increase market concentration [6][18] Summary by Sections Industry Overview - The closing index for the industry is 8430.03, with a 52-week high of 9323.49 and a low of 6764.34 [2] Recent Market Performance - The A-share pharmaceutical sector rose by 2.67% from November 24 to November 28, 2025, outperforming the CSI 300 index by 1.03 percentage points [19][35] - The Hang Seng Healthcare Index increased by 3.64%, outperforming the Hang Seng Index by 1.1 percentage points [35][36] Industry Insights and Investment Recommendations 1. **Innovative Drugs**: The long-term trend for innovative drugs is positive, with China's capabilities in global competition strengthening [9][21] - Recommended stocks include Innovent Biologics, Kintor Pharmaceutical, and others [10][22] 2. **Medical Devices**: The medical device sector is showing signs of recovery, with leading companies reporting improved performance in Q3 [10][26] - Recommended stocks include Mindray, Aohua Endoscopy, and others [27][28] 3. **Traditional Chinese Medicine**: The sector is under pressure but is expected to benefit from basic drug policies and innovation [31][32] - Recommended stocks include Zhaoke Ophthalmology, Fangsheng Pharmaceutical, and others [31][32] 4. **Retail Pharmacy**: The retail pharmacy sector is expected to see increased concentration, with leading pharmacies benefiting from enhanced service capabilities and supply chain management [6][34] - Recommended stocks include Yifeng Pharmacy and Dazhong Pharmacy [7][34]

中证报中证网讯(记者张韵)11月27日，平安医疗健康混合基金经理周思聪在中国证券报"中证点金汇"直 播间表示，虽然近期板块行情有所调整，但创新药大的产业趋势和行情都远未结束。当下创新药行业面 临有利的技术背景、政策环境和利率条件，今年或是中国创新药第一阶段行情的起点，一旦进入到基本 面驱动的行情下，中国创新药行业不排除走出长达10年维度的长期行情。 因此，展望2026年，创新药市场的叙事或将从估值重估转向基本面落地。能否持续产出有价值的创新成 果，以及能否将这些成果高效地转化为商业收入，或是决定未来公司价值的核心。结合三季报数据，可 以看到，创新药行业整体正在快速跨过盈亏平衡线，后续有望看到更加显著的利润改善。 她认为，今年创新药板块一度强劲反弹，标志着中长期维度大行情周期的第一阶段——估值重估的开 启。BD(商务拓展)交易的快速增长验证了国内创新药研发的能力，并开启了一个新的价值创造渠道。 此前演绎的创新药板块行情更多也是BD交易带来的投资情绪的好转，还没有演绎创新药行业的业绩主 线。 ...

Group 1 - The innovative drug sector is leading the market, with Kangfang Biotech and 3SBio both rising over 8%, contributing to a 3.5% increase in the Hang Seng Innovative Drug ETF (159316) [1] - The Hang Seng Innovative Drug ETF has attracted a total of 849 million in capital over the past 20 days, bringing its latest scale to 2.961 billion [1] - The ETF is the only one tracking the Hang Seng Hong Kong Stock Connect Innovative Drug Index, which has recently been updated to exclude CXO, achieving a "100% purity" in innovative drug representation [1] Group 2 - The innovative drug sector is experiencing a significant upward trend, with attention on domestic innovative drug companies participating in the upcoming ESMO conference in Berlin from October 17 to 21, 2025 [1] - Companies to watch include Kangfang Biotech, Kelun-Biotech, Hengrui Medicine, Rongchang Biotech, Junshi Biosciences, and Jinfang Medicine, particularly for new data releases in dual antibodies and ADC technologies [1] - Huafu Securities expresses optimism about the innovative drug industry, predicting a transformative growth over the next 5-10 years driven by overseas business development, continuous data catalysts, and new product sales expansion [1]

Group 1 - The core viewpoint is that China's innovative pharmaceutical industry is experiencing a transformation driven by "quantitative changes leading to qualitative changes," with a positive outlook for the next 5-10 years [1] - Key driving factors for the industry include overseas business development (BD), continuous data catalysis, and the ramp-up of new product sales [1] - The focus of the innovative pharmaceutical market has shifted from broad valuation recovery to the ability of companies to deliver on fundamentals, with those possessing excellent clinical data, strong commercialization capabilities, and successful overseas potential expected to be the future winners [1] Group 2 - The upcoming European Society for Medical Oncology (ESMO) annual meeting is anticipated to showcase clinical data from Chinese innovative drugs, which is expected to be a focal point for the market [1] - Attention is also recommended on the third-quarter performance reports and the national medical insurance negotiations scheduled for November [1] - The Biopharmaceutical ETF (512290) tracks the CS Biomedicine Index (930726), which selects listed companies in biotechnology, pharmaceuticals, and medical services from the Shanghai and Shenzhen markets to reflect the overall performance of the biopharmaceutical sector [1]

Core Viewpoint - The innovative drug sector experienced a significant rally ahead of the upcoming ESMO conference, with notable stock performances and positive market sentiment regarding clinical data releases and business development collaborations [1] Group 1: Market Performance - As of the midday close on October 15, the innovative drug index (886015.TI) rose by 2.35% [1] - Companies such as Guangsheng Tang and Anglikang saw their stocks hit the daily limit up, while others like Shutaishen and Qianyan Biology also recorded substantial gains [1] Group 2: ESMO Conference Insights - The European Society for Medical Oncology (ESMO) conference is scheduled to take place from October 17 to 21 in Berlin, Germany, where significant clinical research results are expected to be presented [1] - The market is particularly optimistic about the release of clinical data from domestic innovative drugs and the progress of business development collaborations [1] Group 3: Investment Opportunities - Haitong International suggests focusing on biotech pipeline advancements, highlighting key clinical data from companies such as Heng Rui (HER2 ADC), Kangfang Bio (AK112), and others as potential catalysts [1] - Long-term perspectives from Huafu Securities indicate that China's innovative drug sector is undergoing a transformation, with a positive outlook on industry trends over the next 5 to 10 years [1] - Investment strategies should consider companies that are expected to meet business development expectations and have strong commercial growth support [1]

Investment Rating - The report maintains an "Outperform" rating for the biopharmaceutical industry [1]. Core Insights - The report is optimistic about the trend of innovative drugs, particularly focusing on the upcoming ESMO conference and national medical insurance negotiations [1][3]. - The innovative drug sector is expected to experience a qualitative change driven by quantitative growth over the next 5-10 years, with business development (BD) overseas, continuous data catalysts, and new product sales driving the rise of innovative drugs [3]. Summary by Sections 1. Innovative Drug Highlights - uniQure's gene therapy AMT-130 for Huntington's disease showed significant results in a key I/II clinical trial, with a 75% reduction in disease progression at high doses [3][5]. - Novartis acquired Akero Therapeutics for $5.2 billion, focusing on FGF21-targeted therapies for MASH, with the core asset being efruxifermin, currently in Phase III trials [22][23]. - The report emphasizes the importance of clinical data from the upcoming ESMO conference and the third-quarter earnings reports, as well as the November national medical insurance negotiations [3]. 2. Industry Catalysts and Strategies - The report suggests focusing on companies with strong clinical data, commercialization capabilities, and potential for successful international expansion, recommending specific companies in both the Biopharma and Pharma sectors [3]. - Suggested companies include: - Pharma: CSPC Pharmaceutical Group, China Biologic Products, and Hengrui Medicine [3]. - Biopharma: Innovent Biologics, Kelun-Biotech, and Zai Lab [3]. 3. Investment Recommendations - The report recommends a dual focus on Biotech and generic-to-innovative companies with potential catalysts, highlighting specific companies in each category [3]. - Suggested Biotech companies include: EdiGene, CanSino Biologics, and I-Mab Biopharma [3]. - Suggested generic-to-innovative companies include: Jingxin Pharmaceutical, Enhua Pharmaceutical, and Changchun High-tech [3].

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" [2]. Core Views - Short-term policy disruptions do not alter long-term industry trends, and there is a recommendation to focus on the Q3 earnings report [2][3]. - The recent performance of the pharmaceutical sector has been relatively weak, with a weekly return of -1.20% and a monthly return of -3.62% compared to the CSI 300 index [3][11]. - Key factors affecting the market include recent agreements in the U.S. regarding drug pricing, significant mergers and acquisitions by multinational corporations, and legislative actions impacting Chinese biotech companies [3][11]. Summary by Sections Market Performance - The pharmaceutical and biotechnology sector's weekly return was -1.20%, ranking 25th among 31 sub-industry indices [3][11]. - The Chinese pharmaceutical index has shown a monthly return of -3.62%, ranking 23rd among the same indices [11][21]. Policy Dynamics - On October 9, the National Medical Products Administration announced measures to expedite post-marketing research for traditional Chinese medicine injections [3][11]. - On October 11, the National Healthcare Security Administration issued a notice to strengthen monitoring of drug pricing issues in retail pharmacies [3][11]. Industry Outlook - Despite short-term policy impacts, the long-term trend for innovative drug companies remains positive, with a focus on the next 2-3 years as a critical period for growth [3][11]. - The CXO sector is recovering, and there is an expectation of sustained growth in performance, which may restore market confidence [3][11]. Q3 Earnings Expectations - Anticipated strong Q3 performance in various segments, including medical devices, traditional Chinese medicine, and raw material pharmaceutical companies [3][4]. - Specific companies to watch include United Imaging Healthcare, Kaili Medical, and others in the high-end medical device sector [4][12]. Sub-industry Performance - Among sub-industries, traditional Chinese medicine showed the highest weekly return of 1.51%, while medical services had a weekly return of -3.37% [11][28]. - The medical device sector is expected to stabilize or reverse in Q3, with several companies recommended for attention [4][12]. Valuation Metrics - The current price-to-earnings (P/E) ratio for the pharmaceutical and biotechnology sector is 30.88, which is above the historical average of 29.23 [15][18]. - The sector's valuation is at a historically low level, indicating potential investment opportunities [15][18].

Core Viewpoint - The "innovative drug" sector is experiencing a rebound after a period of decline, with the Hong Kong Stock Connect Innovative Drug ETF (520880) showing a year-to-date increase of over 120% as of September 9, 2023 [1][2] Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) has seen a significant recovery, turning positive after recent pullbacks [1] - The fund manager, Feng Chen, noted that the biopharmaceutical sector's recent underperformance is due to multiple factors, including a lack of major business development catalysts and external regulatory concerns [1] - The ETF has attracted over 600 million yuan in capital over the last 13 trading days, indicating strong investor interest [2] Group 2: Industry Outlook - Feng Chen believes that the current market adjustment may provide a buying opportunity for high-quality innovative drug companies, as the macro environment is favorable for the sector [1] - The Hang Seng Hong Kong Stock Connect Innovative Drug Selective Index has been revised to exclude CXO companies, focusing solely on 14 innovative drug R&D firms, which enhances its representation of the domestic innovative drug sector [2] - The index has achieved a year-to-date increase of 119.75% before the revision, outperforming other innovative drug indices [2] Group 3: Fund Characteristics - The Hong Kong Stock Connect Innovative Drug ETF (520880) is the largest and most liquid ETF tracking the revised index, with a fund size exceeding 1.7 billion yuan and an average daily trading volume of 521 million yuan [2] - The ETF supports intraday T+0 trading and is not subject to QDII quota restrictions, making it an attractive option for investors [2]